The FDA caused a stir last week when it approved a new, generic version of mifepristone—the abortion medication that has safely, effectively and privately ended pregnancies for 25 years. Many mainstream outlets made it sound like a dramatic policy reversal, but really it was a procedural box check. Meanwhile, the Trump administration is already laying the groundwork to undermine access, announcing a so-called “safety review” based on flawed data and false claims. As reproductive rights advocates like Mini Timmaraju have pointed out, this is gaslighting—pretending to be moderate while plotting restrictions. That’s why protecting mifepristone still matters now.
At least there was some progress this week in menopause care: The FDA signaled plans to remove the “black box” warning on certain hormone treatments that has long stoked fear and confusion. Experts say the label was based on outdated science and has caused real harm, leaving countless women to suffer unnecessarily. For once, the agency seems poised to get this one right.











